GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...

Renaissance Investment Management, an investment management company, released its Q1 2025 “Small Cap Growth Strategy” ...

I remember trying some of her WeightWatchers snacks and being surprised by how much I liked them. Related: How psychedelic ...

Hims & Hers (HIMS) defends recovery with personalized healthcare adoption, GLP-1 partnerships, and profit growth. Click here ...

GLP-1 receptor agonists may significantly reduce the risk for cardiovascular events in patients with rheumatoid arthritis ...

Genetic factors may explain why some people don't lose weight even when following nutritious diets, although health improvements can still be seen regardless of weight changes.

Martin Vollmer, biopharma program manager at Agilent Technologies, spoke to LCGC International about the evolving importance of glucagon-like peptide-1 (GLP-1) therapeutics and the challenges they ...